Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BetterLife Pharma ( (TSE:BETR) ) has shared an announcement.
BetterLife Pharma said it will participate in the YAFO Capital Access Asia 2025 Partnering Forum during JPM Week in San Francisco, positioning the company to meet investors, pharmaceutical partners and strategic advisors from North America and Asia as it advances its flagship neurological drug candidate BETR-001. Chief executive Dr. Ahmad Doroudian will also attend a slate of high-profile industry gatherings, including the H7 Life Science Investment Forum, WuXi Global Forum 2026 and the DARPA and Ferocity Capital Biodefence Summit, where he will hold one-on-one meetings to discuss BetterLife’s development strategy for BETR-001, potentially broadening the company’s financing options, partnership prospects and visibility in the global life sciences and biodefence ecosystems.
The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and negative equity) and bearish technical trend signals. Improving TTM cash burn and a set of positive corporate updates provide some support, but valuation remains constrained by unprofitability and lack of dividend.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a proprietary, non-hallucinogenic and non-controlled derivative of LSD aimed at treating various neurological disorders, including traumatic brain injury, post-traumatic stress disorder and cluster headache. BETR-001 is currently in preclinical and IND-enabling studies and is protected by a synthesis patent, with additional composition and method-of-use patents pending that could extend coverage to around 2042; the company also owns a separate drug candidate targeting viral infections for which it is pursuing strategic alternatives.
Average Trading Volume: 98,990
Technical Sentiment Signal: Sell
Current Market Cap: C$6.84M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.